MRVI vs. KROS, DYN, AMPH, GERN, GLPG, PTCT, TGTX, RNA, RCKT, and CPRX
Should you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include Keros Therapeutics (KROS), Dyne Therapeutics (DYN), Amphastar Pharmaceuticals (AMPH), Geron (GERN), Galapagos (GLPG), PTC Therapeutics (PTCT), TG Therapeutics (TGTX), Avidity Biosciences (RNA), Rocket Pharmaceuticals (RCKT), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical preparations" industry.
Keros Therapeutics (NASDAQ:KROS) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment and dividends.
In the previous week, Maravai LifeSciences had 7 more articles in the media than Keros Therapeutics. MarketBeat recorded 7 mentions for Maravai LifeSciences and 0 mentions for Keros Therapeutics. Maravai LifeSciences' average media sentiment score of 0.98 beat Keros Therapeutics' score of 0.72 indicating that Keros Therapeutics is being referred to more favorably in the media.
Keros Therapeutics presently has a consensus target price of $86.00, suggesting a potential upside of 55.83%. Maravai LifeSciences has a consensus target price of $11.56, suggesting a potential upside of 49.68%. Given Maravai LifeSciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Keros Therapeutics is more favorable than Maravai LifeSciences.
Keros Therapeutics has a net margin of 0.00% compared to Keros Therapeutics' net margin of -41.19%. Keros Therapeutics' return on equity of -1.31% beat Maravai LifeSciences' return on equity.
71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 28.0% of Keros Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Maravai LifeSciences received 18 more outperform votes than Keros Therapeutics when rated by MarketBeat users. Likewise, 67.06% of users gave Maravai LifeSciences an outperform vote while only 66.10% of users gave Keros Therapeutics an outperform vote.
Maravai LifeSciences has higher revenue and earnings than Keros Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.
Keros Therapeutics has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500.
Summary
Maravai LifeSciences beats Keros Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Maravai LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Maravai LifeSciences Competitors List
Related Companies and Tools
